Management tracks: Myovant, Alkahest

Women’s health and endocrine disease company Myovant Sciences Ltd. (NYSE:MYOV) named Kim Sablich chief commercial officer and Jeff Nornhold SVP of pharmaceutical operations and development. Sablich was VP of primary care marketing in the U.S. for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), and Nornhold was SVP of technical operations for Impax Laboratories Inc. Impax merged with Amneal Pharmaceuticals LLC in May to form generics company Amneal Pharmaceuticals Inc. (NYSE:AMRX).

Age-related disease company Alkahest Inc. (San Carlos, Calif.) hired Elizabeth Jeffords as chief commercial and strategy officer. She was VP of the U.S. ophthalmology portfolio of the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)...